Navigation Links
FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer
Date:10/16/2007

rative treatment-related non-hematological adverse events reported in patients treated with capecitabine alone included: peripheral sensory neuropathy 16% (Grade 3/4: 0%), palmar-plantar erythrodysesthesia (hand-foot syndrome) 63% (Grade 3/4: 17%), fatigue/asthenia 29% (Grade 3/4: 4%), nausea 40% (Grade 3/4: 2%), diarrhea 39% (Grade 3/4: 9%), vomiting 24% (Grade 3/4: 2%), myalgia/arthralgia 5% (Grade 3/4: <1%), anorexia 15% (Grade 3/4: 1%), stomatitis/mucositis 20% (Grade 3/4: 3%), alopecia 3% (Grade 3/4: 0%), abdominal pain 14% (Grade 3/4: 1%), nail disorder 10% (Grade 3/4: <1%), musculoskeletal pain 5% (Grade 3/4: 0%), and constipation 6% (Grade 3/4: <1%). Treatment-related hematological adverse events of Grade 3/4 severity reported in patients treated with capecitabine alone included: neutropenia 11% and leukopenia 6%.

IMPORTANT SAFETY INFORMATION

TOXICITY IN HEPATIC IMPAIRMENT

IXEMPRA (ixabepilone) in combination with capecitabine is contraindicated in patients with AST or ALT >2.5 x ULN or bilirubin >1 x ULN due to increased risk of toxicity and neutropenia-related death.

In combination with capecitabine, the overall frequency of Grade 3/4 adverse reactions, febrile neutropenia, serious adverse reactions, and toxicity related deaths was greater in patients with hepatic impairment.

Caution should be used when using IXEMPRA as monotherapy in patients with AST or ALT > 5 x ULN. Use of IXEMPRA in patients with AST or ALT > 10 x ULN or bilirubin >3 x ULN is not recommended.

With monotherapy, Grade 4 neutropenia, febrile neutropenia, and serious adverse reactions were more frequent in patients with hepatic impairment.

CONTRAINDICATIONS

IXEMPRA is contraindicated in patients:

* with a known history of a severe (CTC Grade 3/4) hypersensitivity

reaction to agents containing Cremophor(R) EL or its derivatives such as

polyoxyethylated castor oil.

* who have a baseline neutrophil count <1500 cells/
'/>"/>

SOURCE Bristol-Myers Squibb Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. UW-Madison approves new research institute
2. FDA approves GEs heart-imaging technology
3. Senate approves bill to expand stem cell funding
4. FDA approves advanced digital mammography system
5. Building commission approves Institutes for Discovery
6. UW Board of Regents approves $134 million medical research facility
7. FDA approves Bone Cares Hectorol for treatment of kidney disease
8. Analog people in the Digital Revolution, part II
9. Analog people in the digital revolution
10. Unique Surface Treatment of Novel TSK-GEL ODS Columns Provide Separation of Aqueous and Fat Soluble Vitamins
11. Improve Recovery and Reproducibility with Pre-Treatment of Analytical TSK-GEL G3000SWXL Size Exclusion Columns
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Pittsburgh, PA (PRWEB) November 25, 2014 ... release of its official conference and exposition mobile app, ... available for free download in the App Store for ... as a valuable resource tool before, during and after ... guide containing details on exhibiting companies, technical sessions, Conferee ...
(Date:11/26/2014)... November 26, 2014 CURE™ magazine ... reception on December 5, 2014, in San Francisco prior ... MPN Heroes event will honor clinicians, caregivers, and advocates ... myeloproliferative neoplasms (MPNs). , Special guest speaker Charles ... family's cancer journey at the reception. Over a ...
(Date:11/26/2014)... , 25 novembre 2014 /PRNewswrie/ -- Theravalues Corporation ... il mercato europeo in occasione di Hi Europe 2014 ... ). Si tratta della curcumina con la ... amorfa (senza cristalli) e ingredienti approvati dalle norme europee. ... nella spezia della pianta curcumina ( Curcuma longa ) ...
(Date:11/24/2014)... 2014  Last week, Representatives Gus Bilirakis ... took a bold bipartisan step on behalf of ... Act. Original co-sponsors of the legislation include Representatives ... incentivize drug makers and innovators to "repurpose" major ... cancers, which opens the door to the development ...
Breaking Biology Technology:Pittcon Releases 2015 Mobile App 2CURE Magazine and Incyte to Honor MPN Heroes 2CURE Magazine and Incyte to Honor MPN Heroes 3CURE Magazine and Incyte to Honor MPN Heroes 4La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 2La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 3OPEN Act Introduced to Repurpose Drugs for Rare Diseases 2
... 6 Axelar AB today announced successful,completion of ... phase I/II,clinical trial on cancer patients with its ... inhibitor which has no effects,on the closely related ... on,patients having terminal cancer disease. The results showed ...
... -- Simcere Pharmaceutical Group,(NYSE: SCR ), ... and,innovative anti-cancer pharmaceuticals in China, announced today that ... on Monday, May 18, 2009,after the market closes ... Ren, and chief financial officer, Frank Zhigang Zhao, ...
... 5 Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) today ... For the first quarter of 2009, the Company reported a ... a net loss of $21.1 million, or $0.55 per share, for ... 2009 were $0.7 million compared with $1.8 million for the same ...
Cached Biology Technology:Successful Phase I/II Clinical Trial Results From Cancer Patients Treated With Anti-Cancer Drug From Axelar AB 2Simcere Pharmaceutical Group to Announce 2009 First Quarter Earnings on Monday, May 18, 2009 2Neurocrine Biosciences Reports First Quarter 2009 Results 2Neurocrine Biosciences Reports First Quarter 2009 Results 3Neurocrine Biosciences Reports First Quarter 2009 Results 4Neurocrine Biosciences Reports First Quarter 2009 Results 5Neurocrine Biosciences Reports First Quarter 2009 Results 6Neurocrine Biosciences Reports First Quarter 2009 Results 7Neurocrine Biosciences Reports First Quarter 2009 Results 8
(Date:11/11/2014)... 2014  Forensicon, Inc., a Chicago ... announce the promotion of Yaniv Schiff from ... In Schiff,s new role as Director, he will lead ... forensics examiners and provide leadership within the company,s digital ... http://photos.prnewswire.com/prnh/20141110/157719 Schiff joined Forensicon in ...
(Date:11/7/2014)... -- Leading Biometric companies aim to provide consumers ... transactions.  Companies in focus today are: NXT-ID, Inc. (NASDAQ: ... ), Google Inc. (NASDAQ: GOOG ), Microsoft Corporation ... EBAY ) and MasterCard Inc. (NYSE: MA) NXT-ID, ... authentication company focused on the growing mobile commerce is pleased ...
(Date:11/6/2014)... Medicine, Inc, a Baltimore-based bioinformatics company focused on ... a research collaboration with the international leader in ... CSBR). , "There are many companies utilizing advances ... TumorGraft technology is unique in a way that ... vast amounts of valuable data. Our bioinformatic analysis ...
Breaking Biology News(10 mins):Yaniv Schiff Promoted to Director of Digital Forensics at Forensicon, Inc. 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 3Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 4Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 5Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 6Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2
... issue of Genes & Development, Dr. Karlene Cimprich and ... structure sufficient to activate the ATR-mediated DNA damage checkpoint. ... says Dr. Cimprich. "The ability to precisely define and ... an experimental system will enable us to control, quantitative ...
... one cause of high blood pressure lies within the brain, ... forward by scientists at the University of Bristol, UK, and ... Hidefumi Waki, working in a research group led by Professor ... JAM-1 (junctional adhesion molecule-1), which is located in the walls ...
... Trek: The Next Generation," Geordi La Forge is a ... special implants in his eyes. While the Star Trek ... the 21st century may not have to wait that ... a University of Missouri-Columbia veterinary ophthalmologist, has been working ...
Cached Biology News:Blame the brain for high blood pressure 2MU researcher placing eye implants in cats to help humans see 2
... and efficient method for purification of DNA fragments ... fragments selectively absorbed in the spin column after ... room temperature for PCR product with equal volume ... DNA can be purified with a single prep ...
BlotGel application pool -see Blotters (Semi-Dry) for more info...
lid holder -see Blotters (Semi-Dry) for more info...
When added to either StemSep CD4+ or CD8+ T Cell Enrichment cocktails, human CD45RA TAC is designed to deplete human CD45RA from samples to isolate memory CD4+ or CD8+ T cells....
Biology Products: